T E Warkentin

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. ncbi Venous thromboembolism in heparin-induced thrombocytopenia
    T E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Curr Opin Pulm Med 6:343-51. 2000
  2. ncbi Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia
    T E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Am J Hematol 62:44-8. 1999
  3. ncbi Impact of the patient population on the risk for heparin-induced thrombocytopenia
    T E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Blood 96:1703-8. 2000
  4. ncbi Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays
    T E Warkentin
    Department of Pathology and Molecular Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 6:1304-12. 2008
  5. ncbi Delayed-onset heparin-induced thrombocytopenia and thrombosis
    T E Warkentin
    Hamilton Regional Laboratory Medicine Program, Hamilton General Hospital, Hamilton Health Sciences, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
    Ann Intern Med 135:502-6. 2001
  6. ncbi Limitations of conventional treatment options for heparin-induced thrombocytopenia
    T E Warkentin
    Department of Pathology, McMaster University, Hamilton, Ontario, Canada
    Semin Hematol 35:17-25; discussion 35-6. 1998
  7. ncbi Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization
    T E Warkentin
    Department of Pathology and Molecular Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 8:504-12. 2010
  8. ncbi Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series
    T E Warkentin
    Departments of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 9:2389-96. 2011
  9. ncbi Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia
    C Demers
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Blood 78:2194-7. 1991
  10. ncbi Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis
    T E Warkentin
    McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
    Ann Intern Med 135:589-93. 2001

Detail Information

Publications29

  1. ncbi Venous thromboembolism in heparin-induced thrombocytopenia
    T E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Curr Opin Pulm Med 6:343-51. 2000
    ....
  2. ncbi Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia
    T E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Am J Hematol 62:44-8. 1999
    ..Neither patient had an identifiable hypercoagulable syndrome, other than HIT. HIT may represent a risk factor for the development of multicentric warfarin-induced skin necrosis (WISN)...
  3. ncbi Impact of the patient population on the risk for heparin-induced thrombocytopenia
    T E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Blood 96:1703-8. 2000
    ..HIT-IgG antibodies are more likely to form in patients who undergo cardiac surgery than in orthopedic patients, but among patients in whom antibodies do form, orthopedic patients are more likely to develop HIT. (Blood. 2000;96:1703-1708)..
  4. ncbi Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays
    T E Warkentin
    Department of Pathology and Molecular Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 6:1304-12. 2008
    ..An advantage of the EIA is its simplicity; a disadvantage is that it only indirectly detects heparin-dependent, platelet-activating antibodies ('HIT antibodies')...
  5. ncbi Delayed-onset heparin-induced thrombocytopenia and thrombosis
    T E Warkentin
    Hamilton Regional Laboratory Medicine Program, Hamilton General Hospital, Hamilton Health Sciences, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
    Ann Intern Med 135:502-6. 2001
    ..This syndrome could be caused by high titers of platelet-activating IgG induced by heparin...
  6. ncbi Limitations of conventional treatment options for heparin-induced thrombocytopenia
    T E Warkentin
    Department of Pathology, McMaster University, Hamilton, Ontario, Canada
    Semin Hematol 35:17-25; discussion 35-6. 1998
    ..Moreover, clinically significant cross-reactivity during treatment with danaparoid appears to be uncommon, even in patients in whom in vitro cross-reactivity is demonstrable...
  7. ncbi Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization
    T E Warkentin
    Department of Pathology and Molecular Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 8:504-12. 2010
    ..Heparin-induced thrombocytopenia is an antibody-mediated disorder exhibiting variable frequency in different clinical settings. Antibodies recognize PF4/heparin complexes formed at optimal stoichiometric molar ratios...
  8. ncbi Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series
    T E Warkentin
    Departments of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 9:2389-96. 2011
    ..Although reports of the use of fondaparinux for this indication have thus far been favorable, the diagnosis of HIT in most cases was not based on definitive laboratory confirmation of heparin-dependent, platelet-activating antibodies...
  9. ncbi Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia
    C Demers
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Blood 78:2194-7. 1991
    ..No other side effects were noted. Our experience indicates that ancrod therapy is a reasonable approach for patients with heparin-induced thrombocytopenia who require anticoagulant therapy...
  10. ncbi Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis
    T E Warkentin
    McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
    Ann Intern Med 135:589-93. 2001
    ..CONCLUSION: Warfarin may contribute to the pathogenesis of cancer-associated venous limb gangrene by leading to severe depletion of protein C while at the same time failing to reduce thrombin generation...
  11. ncbi Heparin-induced thrombocytopenia and vascular surgery
    T E Warkentin
    Department of Pathology and Molecular Medicine, and Department of Medicine, McMaster University, and the Hamilton Regional Laboratory Medicine Program, Hamilton, Ontario, Canada
    Acta Chir Belg 104:257-65. 2004
    ..The transience of HIT antibodies provides a rationale for intraoperative use of heparin in a patient who has recovered from HIT and in whom HIT antibodies are no longer detectable...
  12. ncbi Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders
    J C Moore
    Department of Medicine, Faculty of Health Science, McMaster University, Hamilton, ON, Canada
    Blood 98:1842-6. 2001
    ..This study indicates that abnormalities of vWF protease activity are not restricted to patients with the diagnosis of TTP...
  13. ncbi Multimerin is found in the alpha-granules of resting platelets and is synthesized by a megakaryocytic cell line
    C P Hayward
    Department of Medicine, McMaster University Medical Centre, Hamilton, Canada
    J Clin Invest 91:2630-9. 1993
    ..Biosynthesis of multimerin by a megakaryocytic cell line supports endogenous biosynthesis by megakaryocytes as the origin of this platelet alpha-granule protein...
  14. ncbi Off-pump coronary artery bypass grafting for acute heparin-induced thrombocytopenia
    T E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Ann Thorac Surg 72:1730-2. 2001
    ....
  15. ncbi HIT paradigms and paradoxes
    T E Warkentin
    Department of Pathology and Molecular Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 9:105-17. 2011
    ....
  16. ncbi PF4-dependent immunoassays and inferential detection of HIT antibodies
    T E Warkentin
    Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 5:232-4. 2007
  17. ncbi Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings
    G K Lo
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 4:759-65. 2006
    ..CONCLUSIONS: A low pretest clinical score for HIT seems to be suitable for ruling out HIT in most situations (high-negative predictive value). The implications of an intermediate or high score vary in different clinical settings...
  18. ncbi A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins
    J G Kelton
    Michael G DeGroote School of Medicine, Departments of Medicine, Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada Division of Hematology, Duke University Medical Center, Durham, NC, USA Momenta Pharmaceutics, Cambridge, MA, USA
    J Thromb Haemost 10:1446-9. 2012
    ..A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins. J Thromb Haemost 2012; 10: 1446-9...
  19. ncbi Gova/b alloantigen system on human platelets
    J G Kelton
    Department of Medicine, McMaster Medical Centre, Hamilton, Ontario, Canada
    Blood 75:2172-6. 1990
    ..The phenotypic frequencies were Gova/Gova, 26%; Gova/Govb, 55%; Govb/Govb, 19%; giving gene frequencies of 0.532 and 0.468 for Gova and Govb, respectively (n = 33)...
  20. ncbi Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents
    M A Crowther
    Division of Hematology, Department of Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 7:107-10. 2009
    ..However, these new agents have one general limitation--a lack of a widely available antidote. We focus on the management of bleeding in anticoagulated patients, with particular regard to novel anticoagulants...
  21. ncbi Temporal aspects of heparin-induced thrombocytopenia
    T E Warkentin
    Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences Corporation, Ont, Canada
    N Engl J Med 344:1286-92. 2001
    ..CONCLUSIONS: Heparin-induced thrombocytopenia can begin rapidly in patients who have received heparin within the previous 100 days. Heparin-dependent antibodies do not invariably reappear with subsequent heparin use...
  22. ncbi No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure
    T E Warkentin
    J Thromb Haemost 4:281-2. 2006
  23. ncbi Should vitamin K be administered when HIT is diagnosed after administration of coumarin?
    T E Warkentin
    J Thromb Haemost 4:894-6. 2006
  24. ncbi Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings
    A Greinacher
    Institut für Immunologie und Transfusionsmedizin, Ernst Moritz Arndt Universitat Greifswald, Greifswald Germany
    Thromb Res 122:211-20. 2008
    ..We aimed to provide a model that included anticoagulant concentrations and PF4 availability as risk factors influencing the anti-PF4/heparin immune response...
  25. ncbi Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass
    S Selleng
    Institut für Immunologie und Transfusionsmedizin, Ernst Moritz Arndt Universitat Greifswald, Greifswald, Germany
    J Thromb Haemost 6:428-35. 2008
    ....
  26. ncbi Performance characteristics of a rapid assay for anti-PF4/heparin antibodies: the particle immunofiltration assay
    T E Warkentin
    J Thromb Haemost 5:2308-10. 2007
  27. ncbi Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes
    A Greinacher
    Institut für Immunologie und Transfusionsmedizin Ernst Moritz Arndt Universität Greifswald, Greifswald, Germany
    J Thromb Haemost 5:1666-73. 2007
    ..However, the relative utility of functional (platelet activation) vs. antigen [enzyme-immunoassay (EIA)] assays, and the significance of assay discrepancies remain unresolved...
  28. ncbi Clinical sample investigation (CSI) hematology: pinpointing the precise onset of heparin-induced thrombocytopenia (HIT)
    T E Warkentin
    J Thromb Haemost 5:636-7. 2007
  29. ncbi Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors
    R H Aster
    Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI 53201-2178, USA
    J Thromb Haemost 4:678-9. 2006